AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. This platform of biological medicines, […]
immunocore
January 8, 2014 |
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia